BioTuesdays

Category - Markets

Opthea-Logo
Markets

SVB Leerink starts Opthea at OP; PT $33

SVB Leerink launched coverage of Opthea (NASDAQ:OPT) with an “outperform” rating and $33 price target. The stock closed at $13.19 on Nov. 10. “The basis for our recommendation and valuation is our forecast for revenue...

November 11, 2020
Markets

Ladenburg starts Tarsus Pharma at buy; PT $42

Ladenburg Thalmann initiated coverage of Tarsus Pharmaceuticals (NASDAQ:TARS) with a “buy” rating and $42 price target. The stock closed at $23.19 on Nov. 19. Tarsus focuses on the development of novel treatments for...

November 10, 2020
PDS Biotechnology Logo
Markets

HCW ups PDS Biotechnology to buy; PT $6

H.C. Wainwright upgraded PDS Biotechnology (NASDAQ:PDSB) to “buy” from “neutral” with a price target of $6. The stock closed at $2.04 on Nov. 9. In March 2020, HCW downgraded PDS based on dilution, significantly reduced...

November 10, 2020
Syros-Logo
Markets

Brookline starts Syros Pharma at buy; PT $19

Brookline Capital Markets launched coverage of Syros Pharmaceuticals (NASDAQ:SYRS) with a “buy” rating and a 12-to-18-month price target of $19.00. The stock closed at $8.89 on Nov. 9. Syros is developing gene-control...

November 10, 2020
Codiak-Logo
Markets

William Blair starts Codiak BioSciences at OP

William Blair launched coverage of Codiak BioSciences (NASDAQ:CDAK) with an “outperform” rating based on the potential of the company’s novel exosome platform and clinical readouts over the next six-to-nine months...

November 9, 2020
AVEO Pharmaceuticals Logo
Markets

Stifel starts AVEO Pharma at buy; PT $9

Stifel initiated coverage of AVEO Pharmaceuticals (NASDAQ:AVEO) with a “buy” rating and price target of $9. The stock closed at $5.66 on Nov. 6. AVEO is focused on the development and commercialization of targeted...

November 9, 2020
Neovasc Logo
Markets

SVB Leerink cuts Neovasc PT to $2 from $6

SVB Leerink slashed its price target for Neovasc (NASDAQ:NVCN) to $2 from $6, citing timing uncertainty for a U.S. launch of the company’s Reducer stent for percutaneous treatment of refractory angina. The stock closed...

November 6, 2020
inflaRx
Markets

SVB Leerink ups Inflarx to OP; PT to $10 from $7

SVB Leerink upgraded Inflarx (NASDAQ:IFRX) to “outperform” from “market perform” and raised its price target to $10 from $7, citing a “significant disconnect between the promise of IFX-1 in multiple applications, most...

November 6, 2020